Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Besifovir from TDF in Chronic Hepatitis B
NCT04202536Phase 4Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adefovir dipivoxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Rate of subjects who maintained hepatitis B virus (HBV) DNA less than 20 IU/mL at 48 weeks. Status: unknown.
02
Drugs
adefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04202536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202536.